BCRX - CIK 0000882796
BIOCRYST PHARMACEUTICALS INC trades as BCRX and has a market capitalization of $2.08 B, making it the #2072 largest US-listed company by market value. In its fiscal 2017 annual report the company posted revenue of $25.19M, down 4.4% from the prior year and net income of $263.86M. This page tracks BIOCRYST PHARMACEUTICALS INC through 1,935 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 8 fiscal years BIOCRYST PHARMACEUTICALS INC's revenue declined from $74.59M to $25.19M, a compound annual decline rate of 12.7%.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-19 |
| Insider sale notice | 144 | 2026-05-18 |
| Insider trade | 4 | 2026-05-15 |
| Insider sale notice | 144 | 2026-05-13 |
| SCHEDULE 13G | - | 2026-05-12 |
| Quarterly report | 10-Q | 2026-05-06 |
| Major company event | 8-K | 2026-05-06 |
| Major company event | 8-K | 2026-05-04 |
Data include six abstracts featuring new clinical trial and real-world outcomes with ORLADEYO ® (berotralstat), the first and only targeted oral prophylactic therapy for patients with HAE aged 2 and older, and one abstract featuring clinical trial outcomes with navenibart, a long-acting, monoclonal antibody plasma kallikrein inhibitor being investigated for prophylaxis to prevent attacks of HAE.
Studies highlight the significant healthcare and quality-of-life burden associated with hereditary angioedema (HAE) in pediatric patients and their caregivers, demonstrating persistent unmet needs and the importance of optimized disease management to reduce healthcare utilization. Underscoring the role of outcomes research in rare diseases, the research draws on large U.S. insurance claims data and mixed-methods caregiver insights to examine both healthcare resource utilization and the day-to-day impact of pediatric HAE on caregivers.
— Q1 2026 ORLADEYO ® net revenue of $148.3 million (+11% y-o-y; +21% y-o-y on comparable basis excluding European revenue) —
The RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee’s continued service with the company. The RSUs are subject to the terms and conditions of BioCryst’s Inducement Equity Incentive Plan and a restricted stock unit agreement covering the grant.
The largest companies sharing BIOCRYST PHARMACEUTICALS INC's SEC industry classification (biological products, (no diagnostic substances)).
BIOCRYST PHARMACEUTICALS INC (BCRX) has a market capitalization of $2.08 B as of 2026-06-10, ranking #2072 among US-listed companies.
BIOCRYST PHARMACEUTICALS INC reported revenue of $25.19M for fiscal year 2017, a decrease of 4.4% year over year.
Yes. BIOCRYST PHARMACEUTICALS INC reported net income of $263.86M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
— BioCryst grants Irish affiliate of Neopharmed Gentili exclusive license to commercialize navenibart for hereditary angioedema in Europe —